Vanguard Group Inc. Has $76.64 Million Stake in AVANOS MEDICAL, INC. $AVNS

Vanguard Group Inc. lifted its stake in AVANOS MEDICAL, INC. (NYSE:AVNS) by 0.2% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,348,297 shares of the company’s stock after acquiring an additional 8,519 shares during the period. Vanguard Group Inc. owned 11.63% of AVANOS MEDICAL worth $76,641,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. GAMMA Investing LLC grew its holdings in AVANOS MEDICAL by 2,381.6% during the first quarter. GAMMA Investing LLC now owns 17,024 shares of the company’s stock valued at $244,000 after purchasing an additional 16,338 shares during the last quarter. Bank of America Corp DE boosted its holdings in shares of AVANOS MEDICAL by 2.5% during the 4th quarter. Bank of America Corp DE now owns 63,672 shares of the company’s stock worth $1,014,000 after buying an additional 1,537 shares during the period. Principal Financial Group Inc. boosted its holdings in shares of AVANOS MEDICAL by 2.6% during the 1st quarter. Principal Financial Group Inc. now owns 244,063 shares of the company’s stock worth $3,497,000 after buying an additional 6,269 shares during the period. Envestnet Asset Management Inc. grew its stake in AVANOS MEDICAL by 15.8% in the 4th quarter. Envestnet Asset Management Inc. now owns 128,567 shares of the company’s stock valued at $2,047,000 after buying an additional 17,504 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in AVANOS MEDICAL in the 1st quarter valued at $344,000. 95.17% of the stock is currently owned by institutional investors and hedge funds.

AVANOS MEDICAL Price Performance

Shares of AVANOS MEDICAL stock opened at $11.6890 on Friday. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.64 and a quick ratio of 1.58. The company has a market cap of $542.37 million, a PE ratio of -1.16 and a beta of 1.12. The firm has a fifty day moving average price of $11.66 and a two-hundred day moving average price of $12.99. AVANOS MEDICAL, INC. has a fifty-two week low of $9.30 and a fifty-two week high of $25.36.

AVANOS MEDICAL (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, August 5th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). AVANOS MEDICAL had a negative net margin of 66.89% and a positive return on equity of 6.16%. The company had revenue of $175.00 million for the quarter, compared to analyst estimates of $165.50 million. During the same period in the prior year, the company posted $0.34 EPS. AVANOS MEDICAL has set its FY 2025 guidance at 0.750-0.950 EPS. Analysts expect that AVANOS MEDICAL, INC. will post 1.32 EPS for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on AVNS. Zacks Research raised shares of AVANOS MEDICAL to a “hold” rating in a research report on Tuesday, August 12th. Wall Street Zen lowered AVANOS MEDICAL from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 9th. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat.com, AVANOS MEDICAL currently has a consensus rating of “Hold”.

Insider Buying and Selling

In other news, Director Gary Blackford acquired 40,000 shares of AVANOS MEDICAL stock in a transaction on Wednesday, August 13th. The stock was bought at an average price of $10.99 per share, for a total transaction of $439,600.00. Following the transaction, the director owned 40,000 shares of the company’s stock, valued at $439,600. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 2.64% of the stock is currently owned by company insiders.

AVANOS MEDICAL Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.